

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR MARKETING OF
CATEGORY I INNOVATIVE DRUG TQB2450 INJECTION IN COMBINATION
WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF
FIRST-LINE TREATMENT OF SMALL CELL LUNG CANCER ACCEPTED

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Phase III clinical trial of the Group’s Category I antitumor innovative drug TQB2450 Injection in combination with Anlotinib Hydrochloride Capsules for the first-line treatment of small cell lung cancer (“**SCLC**”) has completed its interim analysis and reached the pre-defined end point of the protocol as reviewed by the Independent Data Monitoring Committee (IDMC). The Group has recently submitted a new drug marketing application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People’s Republic of China and the application has been accepted.

Lung cancer is a malignant tumour with high incidence and mortality rates worldwide, and SCLC accounts for 15-20% of all lung cancers. SCLC is very different from non-small cell lung cancer in terms of tissue origin, biological characteristics, response to treatment and prognosis, etc. It is more aggressive and has a poorer prognosis, with a 5-year survival rate of less than 5%. On 29 August 2019, the National Medical Products Administration approved the use of Anlotinib Hydrochloride Capsules as a single drug for the treatment of patients with small cell lung cancer who have progressed or relapsed after receiving at least two previous systemic chemotherapy. TQB2450 Injection is a humanized PD-L1 monoclonal antibody that blocks the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and thereby enhancing the immune response. Early clinical data have demonstrated that TQB2450 injection in combination with Anlotinib Hydrochloride Capsules have synergistic effects on a number of tumour types (e.g. non-small cell lung cancer, soft tissue sarcoma, renal cell carcinoma, endometrial cancer, ovarian cancer, hepatocellular carcinoma, cholangiocarcinoma, etc.).

TQB2450 Injection is another Category I innovative drug recently submitted by the Group after TQ-B3139 and TQ-B3101 Capsules. The Group has been making breakthroughs in the research and development of innovative drugs and its new drug pipeline has gradually entered the harvesting phase.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 13 January 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald